N-[(2Z)-5-tert-butyl-3-(2-methoxyethyl)-1,3-thiazol-2(3H)-ylidene]-2-(pyridin-2-ylmethoxy)-5-(trifluoromethyl)benzamide | 1215229-50-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[(2Z)-5-tert-butyl-3-(2-methoxyethyl)-1,3-thiazol-2(3H)-ylidene]-2-(pyridin-2-ylmethoxy)-5-(trifluoromethyl)benzamide
• CAS: 1215229-50-7
• 化学式: C₂₄H₂₆F₃N₃O₃S
• 分子量: 493.55
• InChiKey: ONSPJLOVGXYMNH-IADYIPOJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.23
• 重原子数：
  34.0
• 可旋转键数：
  7.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  65.71
• 氢给体数：
  0.0
• 氢受体数：
  6.0

文献信息

• NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS
  申请人：Carroll William A.

  公开号：US20100063022A1

  公开（公告）日：2010-03-11

  The present application relates to cannabinoid receptor ligands of formula (I) wherein X 1 , A 1 , R x , R 2 , R 3 , R 4 , and z are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions.

  本申请涉及具有如下式（I）的大麻素受体配体，其中X1、A1、Rx、R2、R3、R4和z如规范中所定义。本申请还涉及包含这类化合物的组合物，以及使用这类化合物和组合物治疗病症和疾病的方法。
• Cannabinoid receptor ligands
  申请人：Abbott Laboratories

  公开号：EP2457903A1

  公开（公告）日：2012-05-30

  The present application relates to cannabinoid receptor ligands of formula (I), wherein X1, A1, Rx, R2, R3, R4, and z are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions.

  本申请涉及式（I）的大麻素受体配体，其中 X1、A1、Rx、R2、R3、R4 和 z 如说明书中所定义。本申请还涉及包含此类化合物的组合物，以及使用此类化合物和组合物治疗疾病的方法。
• SUBSTITUTED BENZAMIDES AS CANNABINOID RECEPTOR LIGANDS
  申请人：Abbott Laboratories

  公开号：EP2346843A2

  公开（公告）日：2011-07-27
• US8846730B2
  申请人：——

  公开号：US8846730B2

  公开（公告）日：2014-09-30
• [EN] NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS<br/>[FR] NOUVEAUX COMPOSÉS COMME LIGANDS DE RÉCEPTEURS DE CANNABINOÏDES
  申请人：ABBOTT LAB

  公开号：WO2010028338A2

  公开（公告）日：2010-03-11

  The present application relates to cannabinoid receptor ligands of formula (I), wherein X1, A1, Rx, R2, R3, R4, and z are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions.